The performance of companies tied to flagship drugs like Viagra presents a nuanced investment landscape . While the initial surge of copyright, fueled by Viagra's remarkable popularity, generated substantial profits , the loss of exclusivity in key markets has introduced substantial uncertainty . Investors are now assessing the effect of rival medi